67 related articles for article (PubMed ID: 7654056)
1. Expression of C-242 antigen in pancreatic ductal adenocarcinoma.
Mäkinen K; Eskelinen M; Lipponen P; Alhava E
Anticancer Res; 1995; 15(4):1605-8. PubMed ID: 7654056
[TBL] [Abstract][Full Text] [Related]
2. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
3. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration.
Chhieng DC; Benson E; Eltoum I; Eloubeidi MA; Jhala N; Jhala D; Siegal GP; Grizzle WE; Manne U
Cancer; 2003 Dec; 99(6):365-71. PubMed ID: 14681945
[TBL] [Abstract][Full Text] [Related]
4. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
Haglund C; Lindgren J; Roberts PJ; Kuusela P; Nordling S
Br J Cancer; 1989 Dec; 60(6):845-51. PubMed ID: 2557879
[TBL] [Abstract][Full Text] [Related]
5. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.
Mäkinen K; Hakala T; Lipponen P; Alhava E; Eskelinen M
Anticancer Res; 1998; 18(1B):615-8. PubMed ID: 9568186
[TBL] [Abstract][Full Text] [Related]
6. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma.
Masaki Y; Oka M; Ogura Y; Ueno T; Nishihara K; Tangoku A; Takahashi M; Yamamoto M; Irimura T
Hepatogastroenterology; 1999; 46(28):2240-5. PubMed ID: 10521973
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of calbindin-D28k expression in lung cancer: analysis of 452 cases.
Castro CY; Stephenson M; Gondo MM; Medeiros LJ; Cagle PT
Mod Pathol; 2000 Jul; 13(7):808-13. PubMed ID: 10912942
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
Giaginis C; Katsamangou E; Tsourouflis G; Zizi-Serbetzoglou D; Kouraklis G; Theocharis S
Med Sci Monit; 2009 May; 15(5):BR148-56. PubMed ID: 19396032
[TBL] [Abstract][Full Text] [Related]
9. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.
Dittert DD; Kielisch C; Alldinger I; Zietz C; Meyer W; Dobrowolski F; Saeger HD; Baretton GB
Hum Pathol; 2008 Jul; 39(7):1002-10. PubMed ID: 18495213
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
12. Tumor markers in patients with pancreatic carcinoma.
Gattani AM; Mandeli J; Bruckner HW
Cancer; 1996 Jul; 78(1):57-62. PubMed ID: 8646727
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma.
Tempero M; Takasaki H; Uchida E; Takiyama Y; Colcher D; Metzgar RS; Pour PM
Am J Surg Pathol; 1989; 13 Suppl 1():89-95. PubMed ID: 2699170
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas.
Jinfeng M; Kimura W; Sakurai F; Moriya T; Mizutani M; Hirai I
Hepatogastroenterology; 2007 Sep; 54(78):1635-40. PubMed ID: 18019682
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.
Lundin J; Roberts PJ; Kuusela P; Haglund C
Anticancer Res; 1995; 15(5B):2181-6. PubMed ID: 8572621
[TBL] [Abstract][Full Text] [Related]
16. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
17. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma.
Lu CD; Morita S; Ishibashi T; Hara H; Isozaki H; Tanigawa N
Cancer; 1999 Mar; 85(6):1250-60. PubMed ID: 10189129
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of netrin-1 expression and its receptors in patients with adenocarcinoma of the pancreas.
Link BC; Reichelt U; Schreiber M; Kaifi JT; Wachowiak R; Bogoevski D; Bubenheim M; Cataldegirmen G; Gawad KA; Issa R; Koops S; Izbicki JR; Yekebas EF
Ann Surg Oncol; 2007 Sep; 14(9):2591-9. PubMed ID: 17549567
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
20. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.
Tascilar M; Skinner HG; Rosty C; Sohn T; Wilentz RE; Offerhaus GJ; Adsay V; Abrams RA; Cameron JL; Kern SE; Yeo CJ; Hruban RH; Goggins M
Clin Cancer Res; 2001 Dec; 7(12):4115-21. PubMed ID: 11751510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
